Pharmacotherapy

Papers
(The H4-Index of Pharmacotherapy is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Changes in serum potassium in people with type 2 diabetes taking sodium‐glucose co‐transporter‐2 inhibitors155
116
Correction to “Relationship of the Revised Anticholinergic Drug Scale With Cultured Cell‐Based Serum Anticholinergic Activity and Cognitive Measures in Older Adults With Mild Cognitive Impairment or R93
Acid‐suppressive drugs: A systematic review and network meta‐analysis of their nocturnal acid‐inhibitory effect87
Safety and efficacy of cefiderocol for off‐label treatment indications: A systematic review83
Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: Current evidence and knowledge gaps56
Empiric dosing strategies to predict lamotrigine concentrations during pregnancy49
Update and narrative review of avian influenza (H5N1) infection in adult patients48
Warfarin dosage in a postpartum woman while breastfeeding: A case report47
Assessment and management of iatrogenic withdrawal syndrome and delirium in pediatric intensive care units across Europe: An ESPNIC survey45
Characterization of lamotrigine disposition changes during and after pregnancy in women with epilepsy40
Correlation Between Analgesic and Sedative Drug Withdrawal and Salivary Cortisol Levels in Children in PICUs : A Prospective Cohort Study40
The Effect of Losartan in Preventing Paclitaxel‐Induced Peripheral Neuropathy in Breast Cancer: A Randomized, Controlled Study37
A Multicenter, Open‐Label Study to Assess the Safety of Nebulized Tissue Plasminogen Activator for the Acute Treatment of Pediatric Plastic Bronchitis: The PLATyPuS Trial36
35
Comparative safety and efficacy of bisphosphonates, denosumab, and parathyroid hormone analogs for osteoporosis following lung transplantation35
Comment on “Evaluation of the safety and tolerability of intravenous undiluted levetiracetam at a pediatric institution”33
Reduced risk of NSAID‐Induced adverse events with concomitant use of misoprostol (MICRO study)28
Optimal starting dosing regimen of intravenous oxytocin for labor induction based on the population kinetic‐pharmacodynamic model of uterine contraction frequency26
Patient safety outcomes for continuous infusion vancomycin as outpatient parenteral antimicrobial therapy26
Response to comment on “Dosing implications for liposomal amphotericin B in pregnancy”24
Probiotic Supplementation as an Adjuvant Therapy in Pediatric Drug‐Resistant Epilepsy: A Double‐Blind Placebo‐Controlled Trial23
Biomarkers in the intensive care setting: A focus on using procalcitonin and C‐reactive protein to optimize antimicrobial duration of therapy23
Evaluation of the safety and tolerability of intravenous undiluted levetiracetam at a pediatric institution23
Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Partial‐ and Full‐Thickness Skin Burns23
0.10084104537964